Form 4: Edgewise Therapeutics Director Equity Grant

Director Badreddin Edris received a grant of restricted stock units and stock options as part of annual compensation.

Summary

• Director Badreddin Edris was granted 5,619 Restricted Stock Units (RSUs) on June 5, 2026.
• Director Badreddin Edris was granted 8,188 stock options with an exercise price of $35.59 on June 5, 2026.
• Both the RSUs and stock options are scheduled to vest on June 2, 2027, or the business day prior to the 2027 annual meeting of stockholders, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Market volatility affecting the value of granted equity instruments.
• Potential for future dilution if additional equity compensation is issued.

Future Outlook

The equity grants vest in one year, signaling a standard annual compensation cycle for board members.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation common in the biotechnology sector to incentivize board oversight and long-term strategic alignment.

Comparison to Industry Standards

• Equity grants for directors are standard practice in the biopharmaceutical industry to attract and retain qualified board members.
• The one-year vesting schedule is consistent with typical corporate governance practices for non-employee directors.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on June 2, 2027.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Form 4, Insider Trading, Equity Compensation, Director Compensation